6106-07-6
L-thyroxine sodium salt
CAS: 6106-07-6
Molecular Formula: C15H20I4NNaO9
6106-07-6 - Names and Identifiers
6106-07-6 - Physico-chemical Properties
| Molecular Formula | C15H20I4NNaO9 |
| Molar Mass | 888.93 |
| Density | 2.381 |
| Melting Point | 207-210 (dec.)(lit.) |
| Specific Rotation(α) | [α]D20 +15～+19° |
| Solubility | cell culture medium: 0.1mg/mL |
| Appearance | powder |
| Color | White to Yellow to Orange |
| BRN | 5721845 |
| Storage Condition | 2-8°C |
| In vivo study | Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03). |
6106-07-6 - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 40 - Limited evidence of a carcinogenic effect |
| Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36 - Wear suitable protective clothing. |
| WGK Germany | 3 |
| RTECS | YP2833760 |
| FLUKA BRAND F CODES | 3-8-10 |
6106-07-6 - Nature
Open Data Verified Data
This product is a synthetic levothyroxine sodium salt, the role and use is similar to the thyroid tablets, due to the purity of the product, the preparation is standardized, the effect is slow, stable, long half-life, large in vivo storage, similar to physiological hormones, so the preferred thyroxine replacement therapy. Oral absorption of an average of 50%.
Last Update：2024-01-02 23:10:35
6106-07-6 - Use
Open Data Verified Data
thyroid hormone replacement therapy drugs. Usage and dosage of oral administration for adults: starting from 25 ~ 50ug per day, once a day; Increasing by 50 ug every 2 weeks; The final dose is 150 ~ 300ug per day; The maintenance dose is 100 ~ 200ug per day; the oral dose for children over 1 year old was 4 ug/kg.d, 25 ~ 50ug daily for less than 1 year old as the starting dose, and later adjusted according to T4 and TSH concentration (for blushing's disease). Intravenous administration was used to treat myxedema Coma.
Last Update：2022-01-01 11:10:37
6106-07-6 - Safety
Open Data Verified Data
- slow metabolism, easy to accumulate poisoning, toxic reaction was Head Pain, palpitations, chest pain, heat intolerance, sweating, excitement, Sleep Initiation and Maintenance Disorders. In severe cases, there may be iatrogenic hyperthyroidism, even Vomit, Diarrhea, Fever, arrhythmia, even angina pectoris and heart failure. The dose should be increased slowly from a small dose to avoid intoxication. After the onset of symptoms of poisoning, the drug should be discontinued for 1 week. Note the patient's liver and kidney function.
- protected from light, sealed and stored at low temperature.
Last Update：2022-01-01 11:10:37
6106-07-6 - Reference Information
| biological activity | L-Thyroxine sodium salt (levodyroxine; T4) is a synthetic thyroid hormone, for the study of hypothyroidism. The DIO enzyme converts L-Thyroxine (T4) to biologically active triiodothyronine (T3). |
| Target | Thyroid Hormone Receptor |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: Sodium Levothyroxine Pentahydrate Visit Supplier Webpage Request for quotationCAS: 6106-07-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Sodium Levothyroxine Pentahydrate Visit Supplier Webpage Request for quotationCAS: 6106-07-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History